Bristol-Myers Squibb Company (BMY) Yield on Cost (YOC): 4.50%
The yield on cost (YOC) for Bristol-Myers Squibb Company (BMY) is 4.50%.
BMY Yield on Cost (YOC) Metrics
YIELD ON COST (YOC)
4.50%
Yield on Cost for BMY
BMY now pays $2.50 per share a year. Measured against the price it actually traded at back then, a long-term holder is earning:
| If you bought | Price then | Yield on cost today |
|---|---|---|
| 10 years ago(2016-06-08) | $73.41 | 3.41% |
| 5 years ago(2021-06-16) | $66.92 | 3.74% |
| 3 years ago(2023-06-06) | $65.48 | 3.82% |
| 1 year ago(2025-06-10) | $49.97 | 5.00% |
| Buying today(at $55.60) | $55.60 | 4.50% |
If you buy today and the dividend keeps growing
Projection: starting from today's 4.50% yield, assuming the dividend keeps compounding at its historical 1.6% rate. Boards set dividends each year, so actual figures will differ.
Today
4.50%
In 3 years
7.59%
In 5 years
10.75%
In 10 years
25.70%
Yield on Cost Calculator
Try your own purchase price, dividend and growth rate for Bristol-Myers Squibb Company (BMY).
Starting Yield
4.50%
Ending YOC
5.71%
Year 15 Dividend
$3.18
Cum. Dividends Recd.
$42.71
| Year | Projected Div. / Share | YoY Dividend Hike | Yield on Cost (YOC) | Total Dividends Recd. |
|---|---|---|---|---|
| Initial | $2.50 | — | 4.50% | $0.00 |
| Year 1 | $2.54 | +1.61% | 4.57% | $2.54 |
| Year 2 | $2.58 | +1.61% | 4.64% | $5.12 |
| Year 3 | $2.62 | +1.61% | 4.72% | $7.74 |
| Year 4 | $2.66 | +1.61% | 4.79% | $10.41 |
| Year 5 | $2.71 | +1.61% | 4.87% | $13.12 |
| Year 6 | $2.75 | +1.61% | 4.95% | $15.87 |
| Year 7 | $2.80 | +1.61% | 5.03% | $18.66 |
| Year 8 | $2.84 | +1.61% | 5.11% | $21.50 |
| Year 9 | $2.89 | +1.61% | 5.19% | $24.39 |
| Year 10 | $2.93 | +1.61% | 5.28% | $27.32 |
| Year 11 | $2.98 | +1.61% | 5.36% | $30.30 |
| Year 12 | $3.03 | +1.61% | 5.45% | $33.33 |
| Year 13 | $3.08 | +1.61% | 5.53% | $36.41 |
| Year 14 | $3.13 | +1.61% | 5.62% | $39.54 |
| Year 15 | $3.18 | +1.61% | 5.71% | $42.71 |
Bristol-Myers Squibb Company Yield on Cost (YOC) Formula & Definition
Yield on cost is the dividend yield measured against your original purchase price, not today's price. As a company raises its dividend, the yield on what you actually paid keeps rising even when the market yield holds steady.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Bristol-Myers Squibb Company Yield on Cost (YOC) FAQ
- What is the yield on cost (YOC) for Bristol-Myers Squibb Company (BMY)?
- The yield on cost (YOC) for BMY stock is 4.50%.
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Christopher S. Boerner